IVMED 80

Drug Profile

IVMED 80

Alternative Names: IVMED-80

Latest Information Update: 01 Dec 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator iVeena Delivery Systems
  • Class Eye disorder therapies
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Keratoconus
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Research Keratoconus

Most Recent Events

  • 08 Nov 2017 IVMED 80 is available for licensing as of 08 Nov 2017
  • 08 Nov 2017 Early research in Keratoconus in USA (Ophthalmic)
  • 08 Nov 2017 Research programme: eye disorder therapeutics - iVeena Delivery Systems receives Orphan Drug status for Keratoconus in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top